For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,
Corporate Communications Department
Telephone: +81-3-6225-1126
Establishment of the Healthcare Company DAIICHI SANKYO HEALTHCARE CO., LTD.
Tokyo, November 25, 2005 -DAIICHI SANKYO COMPANY, LIMITED(Headquarters: Tokyo; President: Takashi Shoda) announced today that its 100% subsidiaries, Sankyo Company, Limited (hereafter, Sankyo; Headquarters: Tokyo; President: Yasuhiro Ikegami) and Daiichi Pharmaceutical Co., Ltd. (hereafter,Daiichi Pharmaceutical; Headquarters: Tokyo, President: Kiyoshi Morita), will establish a new company "DAIICHI SANKYO HEALTHCARE CO., LTD." to integrate the healthcare businesses of both companies.
After the new company is established around December 15 this year, an agreement to separate the healthcare businesses of Sankyo and Daiichi Pharmaceutical for transfer to the new company will be concluded on December 22. The new company is expected to commence business in April 2006. Information on the business plans and profile of the new company will be released after the separation agreement is concluded.
An April 2007 target has been set for the integration of the ethical drugs businesses of Sankyo and Daiichi Pharmaceutical.
Appendix
| Company name |
DAIICHI SANKYO HEALTHCARE CO., LTD. |
Directors and
Corporate Auditor |
President and Representative Director
Moriya Ideguchi (General Manager, Healthcare Division,Sankyo)
Vice president and Director
Yuichi Kano (Director, OTC Division,Daiichi Pharmaceutical)
Director
Hidetoshi Imaizumi (Managing Director,Daiichi Pharmaceutical)
Corporate Auditor
Hisao Koshino (Member of the Board,Sankyo Pharma Inc.) |
| Main business lines |
Manufacture and sale of drugs, quasi drugs, cosmetics, medical devices, food, and beverage, among others |
| Capital |
10 million yen (scheduled for increase after business transfer) |
| December 15 |
New company establishment |
| December 22 |
Conclusion of separation agreement |
| Mid January |
New company extraordinary shareholders meeting |
| April |
Start of new company business |
| Sankyo and Daiichi Pharmaceutical’s Healthcare Business Sales (Fiscal 2004) |
|
Sankyo
|
Daiichi Pharmaceutical
|
|
19.4 billion yen
|
10.2 billion yen
|
| Main Healthcare Products of Sankyo and Daiichi Pharmaceutical |
|
Sankyo
|
Daiichi Pharmaceutical
|
Lulu (cold remedy)
Shin-Sankyo Ichoyaku
(gastrointestinal drug)
Regain (pick-me-up drinks)
Lamisil AT (athlete’s foot medicine)
Viton Hi (vitamin complex) |
Karoyan (hair growth agents)
Patecs (anti-inflammatory analgesic for external use)
Cystina (vitamin complex)
Senlock (gastrointestinal drug) |
End